Samsung Bioepis Starts Direct Commercialization of Byooviz
Samsung Bioepis has begun its direct commercialization of Byooviz, which is a biosimilar to Genentech’s Lucentis - ranibizumab in Europe.
The company has gone ahead...
Daiichi Sankyo Plans to Boost Its Antibody-Drug Conjugate
Daiichi Sankyo has recently made an announcement of its plans to invest almost 300 billion yen, which is equivalent to $1.9 billion, when it...
Hengrui Pharma Inks 20-Year Licensing Agreement with Hansoh
Jiangsu Hengrui Pharmaceuticals, which is a China-based pharmaceutical company that is focused on research, development, and manufacturing, as well as the commercialization of innovative medicines, has gone...
U.S. FDA Approves Weight Loss Pill from Novo Nordisk
The U.S. Food and Drug Administration approves a weight loss pill from Novo Nordisk, therefore giving the Danish drugmaker an edge in the race...
U.S. FDA Approves Bispecific Lunsumio VELO™ by Roche
Roche has made an announcement that the US Food and Drug Administration (FDA) has provided approval for CD20xCD3 bispecific Lunsumio VELO™-mosunetuzumab as a subcutaneous...
Boehringer Ingelheim Moves to Lower Costs for Medicines in the U.S.
Boehringer Ingelheim, which is a 140-year-old family-owned biopharmaceutical company and the one that has made a commitment to enhancing human as well as animal...
Samsung Biologics Acquires GSK’s Human Genome Sciences Site in U.S.
Samsung Biologics has agreed to acquire 100% of Human Genome Sciences from GSK, a move that secures the company’s first U.S.-based biologics manufacturing site...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...